HMGN1 and Dravet syndrome: The most recent study applied HMGN1 CRISPR/Cas9 KO to the SET2 cell line edited to harbor the rearrangement of CRLF2 observed in DS-ALL patients and to the DS-ALL xenograft mouse model [175].